Evidence map›Paper›PMID 29444972›Full record

ArticleNeurology2018

Usefulness of ADAMTS13 to predict response to recanalization therapies in acute ischemic stroke.

Alejandro Bustamante, MingMing Ning, Teresa García-Berrocoso, Anna Penalba, Cristina Boada, Alba Simats, Jorge Pagola, Marc Ribó, Carlos Molina, Eng Lo and 1 more

3 registry-linked trialsOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05836740 phase3completednot on this mapstarted 2023, after this paper: background citation

Efficacy and Safety of Minocycline in Patients With Moderate to Severe Acute Ischemic Stroke: A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase III Trial

TypeinterventionalSponsorBeijing Tiantan HospitalRan2023 to 2024Enrolled1,724ConditionsIschemic Stroke, AcuteArmsMinocycline hydrochloride capsule, Placebo capsules of Minocycline hydrochloride capsules
NCT05836753 phase2unknown statusnot on this mapstarted 2023, after this paper: background citation

Efficacy and Safety of Sarecycline in Patients With Acute Ischemic Stroke After Reperfusion Therapy: A Phase II, Randomized, Multicenter, Double-blind, Single Dose, Placebo-controlled Parallel Trial

TypeinterventionalSponsorBeijing Tiantan HospitalRan2023 to 2023Enrolled120ConditionsIschemic Stroke, AcuteArmsSarecycline Tablet, Placebo tablets of Sarecycline tablets
NCT05836766 phase2unknown statusnot on this mapstarted 2023, after this paper: background citation

Cilostazol Dexborneol Versus Placebo for Microcirculation Dysfunction After Reperfusion Therapy in Patients With Acute Ischemic Stroke With Large Vessel Occlusion: A Phase Ⅱa,Prospective,Multicenter,Randomized, Double-blind,Placebo-controlled Parallel Trial

TypeinterventionalSponsorBeijing Tiantan HospitalRan2023 to 2024Enrolled120ConditionsAcute Ischemic Stroke, Reperfusion, Large Vessel OcclusionArmsY-6 sublingual tablets, Placebo tablets of Y-6 sublingual tablet
3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. ADAMTS13 in the New Era of TTP.International journal of molecular sciences · 2024
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review of studies on dynamic cerebral autoregulation in the acute phase of stroke and the relationship with clinical outcome.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2022
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Alejandro BustamanteFrom the Neurovascular Research Laboratory (A.B., T.G.-B., A.P., C.B., A.S., J.M.), Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Clinical Proteomics Research Center and Cardio-Neurology Clinic (M.N., E.L.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and Stroke Unit (J.P., M.R., C.M.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
MingMing NingFrom the Neurovascular Research Laboratory (A.B., T.G.-B., A.P., C.B., A.S., J.M.), Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Clinical Proteomics Research Center and Cardio-Neurology Clinic (M.N., E.L.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and Stroke Unit (J.P., M.R., C.M.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Teresa García-BerrocosoFrom the Neurovascular Research Laboratory (A.B., T.G.-B., A.P., C.B., A.S., J.M.), Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Clinical Proteomics Research Center and Cardio-Neurology Clinic (M.N., E.L.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and Stroke Unit (J.P., M.R., C.M.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Anna PenalbaFrom the Neurovascular Research Laboratory (A.B., T.G.-B., A.P., C.B., A.S., J.M.), Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Clinical Proteomics Research Center and Cardio-Neurology Clinic (M.N., E.L.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and Stroke Unit (J.P., M.R., C.M.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Cristina BoadaFrom the Neurovascular Research Laboratory (A.B., T.G.-B., A.P., C.B., A.S., J.M.), Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Clinical Proteomics Research Center and Cardio-Neurology Clinic (M.N., E.L.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and Stroke Unit (J.P., M.R., C.M.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Alba SimatsFrom the Neurovascular Research Laboratory (A.B., T.G.-B., A.P., C.B., A.S., J.M.), Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Clinical Proteomics Research Center and Cardio-Neurology Clinic (M.N., E.L.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and Stroke Unit (J.P., M.R., C.M.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Jorge PagolaFrom the Neurovascular Research Laboratory (A.B., T.G.-B., A.P., C.B., A.S., J.M.), Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Clinical Proteomics Research Center and Cardio-Neurology Clinic (M.N., E.L.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and Stroke Unit (J.P., M.R., C.M.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Marc RibóFrom the Neurovascular Research Laboratory (A.B., T.G.-B., A.P., C.B., A.S., J.M.), Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Clinical Proteomics Research Center and Cardio-Neurology Clinic (M.N., E.L.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and Stroke Unit (J.P., M.R., C.M.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Carlos MolinaFrom the Neurovascular Research Laboratory (A.B., T.G.-B., A.P., C.B., A.S., J.M.), Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Clinical Proteomics Research Center and Cardio-Neurology Clinic (M.N., E.L.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and Stroke Unit (J.P., M.R., C.M.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Eng LoFrom the Neurovascular Research Laboratory (A.B., T.G.-B., A.P., C.B., A.S., J.M.), Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Clinical Proteomics Research Center and Cardio-Neurology Clinic (M.N., E.L.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and Stroke Unit (J.P., M.R., C.M.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Joan MontanerFrom the Neurovascular Research Laboratory (A.B., T.G.-B., A.P., C.B., A.S., J.M.), Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Clinical Proteomics Research Center and Cardio-Neurology Clinic (M.N., E.L.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and Stroke Unit (J.P., M.R., C.M.), Hospital Universitari Vall d'Hebron, Barcelona, Spain. joan.montaner@vhir.org.
Vall d'Hebron Institut de Recerca · ES

Funding

Proteomic Profiling of Patent Foramen Ovale Related Neurovascular InjuryR01NS067139 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI NING, MINGMING · 2010 to 2023
$3.7M
Thrombolysis Profiles in tPA ResponseR01NS093415 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI LO, ENG H., NING, MINGMING · 2015 to 2019
$1.9M
NINDS NIH HHS R01 NS067139NINDS NIH HHS R01 NS093415
6 · The paper itself

Abstract

objectiveWe aimed to analyze ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) in relation to arterial recanalization in patients treated with IV tissue plasminogen activator (tPA) and in relation to futile recanalization in patients treated with mechanical thrombectomy.

methodsAcute ischemic stroke patients (n = 108) with documented arterial occlusions treated with IV-tPA were selected. ADAMTS13 activity was measured by ELISA in samples collected before treatment. Recanalization was assessed at 2 hours by transcranial Doppler. In 78 consecutive patients treated with endovascular thrombectomy, ADAMTS13 antigen was measured by ELISA and futile recanalization was defined as complete recanalization plus modified Rankin Scale score >2 at 3 months. Independent predictors of recanalization and futile recanalization were determined by logistic regression, adjusted by age, NIH Stroke Scale score, and time from stroke onset.

resultsPatients who achieved tPA-induced recanalization had higher baseline ADAMTS13 activity (78.1% [68%-88%] vs 70.1% [61%-79%],

conclusionsA reduced ADAMTS13 was associated with poor response to recanalization therapies. If confirmed in future prospective studies, a panel of blood biomarkers including ADAMTS13 might be a useful tool to guide reperfusion therapies.

Indexed as

ADAMTS13 ProteinAgedAged, 80 and overBiomarkersBrain IschemiaCohort StudiesFemaleFibrinolytic AgentsHumansMaleMechanical ThrombolysisMiddle AgedPrognosisStrokeThrombolytic TherapyTissue Plasminogen ActivatorADAMTS13 ProteinADAMTS13 protein, humanBiomarkersFibrinolytic AgentsTissue Plasminogen Activator

Identifiers

PMID29444972
PMCPMC5874450
OpenAlexW2785667195

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.